Form 4: FibroGen CEO Wettig Thane Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
CEO Wettig Thane of FibroGen, Inc. reports disposing of 20,840 shares of common stock to cover tax obligations arising from vesting restricted stock units.
Summary
- On August 1, 2024, FibroGen CEO Wettig Thane disposed of 20,840 shares of common stock.
- The transaction was executed to satisfy a tax obligation related to the vesting of restricted stock units.
- The price per share was $0.47.
- Following the transaction, Wettig Thane directly owns 424,679 shares of FibroGen common stock and indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Disposals to cover tax obligations are common.
Stakeholder Impact
- The disposal of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the transaction.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of stock disposal transaction |
| 08/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.